AI Investment Business

Pearl's $58 Million Bet on Dental AI

Dr Ali Vatan Ali Vatan
·

The largest single investment in dental AI history raises a question every dentist should be asking: is this the future, or is it a bubble?

Pearl's $58 Million Bet on Dental AI

Pearl just raised $58 million in a Series B round, making it the largest single investment in dental AI history. My first reaction wasn’t excitement; it was a question. A lot of people have been speculating that this AI race is becoming a bit of a bubble, and I think they might have a point.

What Pearl actually does

Credit where it’s due. Pearl makes Second Opinion, an FDA-cleared AI system that analyses dental radiographs and highlights potential pathology. It was one of the first of its kind to receive regulatory clearance, now authorised in over 120 countries. TIME magazine named it one of its Best Inventions (Pearl, 2024).

They’ve also launched an AI-powered clinical calibration tool designed to standardise how dentists read radiographs. If you’ve worked in a group practice, you’ll know diagnostic consistency between clinicians is a real problem. Two dentists, same radiograph, different conclusions. A calibration tool that reduces that variability is a good idea in principle.

Then there’s Claimcheck, an AI-powered system that validates insurance claims before submission, flagging errors and attaching AI-annotated radiographs to support the claim (BusinessWire, 2025). Insurance claim rejections are a massive headache for practices, so this is a smart move commercially.

The money

Pearl’s $58 million Series B was led by Left Lane Capital, with participation from Smash Capital, Alpha Partners, and existing investors Craft Ventures and Neotribe Ventures. Total raised: over $80 million (TechCrunch, 2024).

Pearl isn’t alone. The oral health AI sector received more than $140 million in venture capital in 2024 alone (Becker’s, 2024). VideaHealth, Overjet, and others have all raised significant rounds. The ADA itself made a strategic investment in Pearl in December 2024, a signal the dental establishment is taking this seriously.

But investment reflects confidence, not proof. Investors are betting dental AI will become standard practice. They might be right. They might also be early, which in venture capital is functionally the same as being wrong.

The bubble question

The future of AI is uncertain. It’s so powerful that we’re not sure where it’s going to land, and that uncertainty cuts both ways.

The clinical applications are real. AI-assisted radiograph analysis can improve diagnostic accuracy, catch things that get missed, and create a more standardised approach to care. Multiple studies and FDA clearances back this up.

But it’s very easy to be fooled by the magic of it. I’ve watched demos where AI annotates a radiograph in seconds, highlighting caries, bone loss, and periapical pathology with neat coloured boxes. It looks incredible. But looking incredible and being clinically indispensable are two different things.

The real question isn’t whether AI can detect disease on a radiograph (it clearly can). The question is whether it changes patient outcomes at scale: earlier treatment, better treatment, fewer missed diagnoses that actually matter. Only time and real-world data will tell.

What dentists should be thinking about

These tools are coming. Some are already here. The ones that prove themselves with solid clinical evidence will likely become as standard as digital radiography. You don’t need to be an early adopter, but you do need to understand what these systems do.

What concerns me is the marketing pressure. When a company has $58 million in funding, it needs to grow. Growth means sales. Sales means convincing dentists they need this technology right now. Some practices will adopt it not because it genuinely improves care, but because it looks good in their marketing or because they’re afraid of being left behind. That’s not a good reason to adopt any clinical tool.

The ADA’s move

The ADA investing in Pearl is significant. The ADA doesn’t typically make venture investments. This signals a belief at institutional level that AI in dental imaging is not a fad.

But the ADA also proposed a standards document covering AI in dentistry in 2024 (Becker’s, 2024). Standards mean guardrails, and guardrails exist because the people setting them recognise that powerful technology can cause harm as easily as it can help.

Where I stand

Only time will tell how useful this actually is for the public. That’s not a cop-out; it’s the honest position. We’re in the early chapters of dental AI.

Pearl’s products are real, their regulatory credentials are solid, and they have institutional support. But $58 million creates expectations, and expectations create pressure to deliver returns. I hope that pressure leads to better products rather than better marketing.

The goal isn’t to have the fanciest technology in the surgery. The goal is to give patients better care. If AI does that, brilliant. If it doesn’t, no amount of venture capital will save it.

References